Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | KMO | O15229 | 3/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29514695 | 1.00 | GSK3B (0.61) | GSK3BTSHRKMOPTPN1HSD11B1 | |
| Bromide SCHEMBL5722043 | 0.98 | GSK3B (0.59) | GSK3BTSHRKMOPTPN1HSD11B1 | |
| SCHEMBL8004853 | 0.84 | GSK3B (0.57) | GSK3BPTPN1 | |
| SCHEMBL6514586 | 0.84 | GSK3B (0.57) | GSK3BTSHRPTPN1 | |
| SCHEMBL5054876 | 0.84 | GSK3B (0.57) | GSK3BKMOPTPN1 | |
| SCHEMBL29628383 | 0.84 | GSK3B (0.57) | GSK3BPTPN1 | |
| SCHEMBL9015106 | 0.83 | TSHR (0.61) | TSHRKMOHSD11B1HDAC3HDAC4 | |
| SCHEMBL23112482 | 0.82 | GSK3B (0.55) | GSK3BPTPN1 | |
| SCHEMBL311275 | 0.82 | GSK3B (0.60) | GSK3BTSHRPTPN1 | |
| SCHEMBL3973133 | 0.82 | GSK3B (0.55) | GSK3BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 462 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110305048-A | One kind preparing α-sulfuryl ketone compounds synthetic method by α, α-two bromo ketone one kettle way | 温州大学 | 2019-10-08 | — | — | CN | claimed |
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4663242-A1 | TARGETING THE ENERGY COUPLING FACTOR (ECF) TRANSPORTERS AS NOVEL ANTIMICROBIAL TARGET | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2025-12-17 | — | — | EP | disclosed |
| US-12473263-B2 | Bicyclic inhibitors of CBX chromodomains | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | PRISM MEDICINES, INC. | 2025-01-09 | — | — | US | disclosed |
| US-12150934-B2 | Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases | BANTAM PHARMACEUTICAL, LLC (US) | 2024-11-26 | — | — | US | disclosed |
| EP-3997096-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2024-08-28 | — | — | EP | disclosed |
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-4143148-A | ANTI-ULCER THIAZOLINE DERIVATIVES | JOHN WYETH & BROTHER LIMITED (GB) | 1979-03-06 | — | — | US | disclosed |
| US-4127660-A | ANTIULCER | JOHN WYETH & BROTHER LIMITED (GB) | 1978-11-28 | — | — | US | disclosed |
| US-4053611-A | SUBSTITUTED PHENOXYALKYL QUATERNARY AMMONIUM COMPOUNDS AS ANTIARRHYTHEMIC AGENTS | THE DOW CHEMICAL COMPANY (US) | 1977-10-11 | — | — | US | disclosed |
| US-4049814-A | Substituted phenoxyalkyl quaternary ammonium compounds as antiarrhythemic agents | THE DOW CHEMICAL COMPANY (US) | 1977-09-20 | — | — | US | disclosed |
| US-4042712-A | Substituted phenoxyalkyl quaternary ammonium compounds as antiarrhythemic agents | THE DOW CHEMICAL COMPANY (US) | 1977-08-16 | — | — | US | disclosed |
| US-4041178-A | Substituted phenoxyalkyl quaternary ammonium compounds as antiarrhythemic agents | THE DOW CHEMICAL COMPANY (US) | 1977-08-09 | — | — | US | disclosed |
| US-4021575-A | Substituted phenoxyalkyl quaternary ammonium compounds as antiarrhythmic agents | THE DOW CHEMICAL COMPANY (US) | 1977-05-03 | — | — | US | disclosed |
| US-4013692-A | ANTIINFLAMMATORY, ANTIPYRETICS, ANALGESICS | RIKER LABORATORIES, INC. (US) | 1977-03-22 | — | — | US | disclosed |
| US-3997557-A | ANTIARRHYTHMIA, CNS DEPRESSANT, ANTIINFLAMMATORY, HYPOTENSIVE | AMERICAN HOECHST CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
| US-3931407-A | ANTIINFLAMMATORY, ANALGESIC | AMERICAN HOECHST CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473263-B2 | Bicyclic inhibitors of CBX chromodomains | CBX2, CBX3, CBX6 | GSK3B 2969/4885TSHR 4302/4885KMO 3052/4885 |
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | GSK3B 3183/4885TSHR 156/4885KMO 337/4885 |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | GSK3B 440/4885TSHR 3921/4885KMO 3233/4885 |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | GSK3B 3183/4885TSHR 156/4885KMO 337/4885 |
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | JAK2, JAK1, JAK3 | GSK3B 529/4885TSHR 2579/4885KMO 1818/4885 |
| US-12150934-B2 | Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases | KRAS, TP53, CCNA1 | GSK3B 1419/4885TSHR 2933/4885KMO 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.